Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
For small-cell lung cancer patients, ditching preventive brain radiation in favor of MRI monitoring could be the smarter move. The MAVERICK phase 3 trial found that MRI surveillance alone cut the risk of cognitive failure or death by 40% compared to adding prophylactic cranial irradiation (PCI). Patients who skipped radiation also experienced far fewer side effects like fatigue, hair loss, and nausea.
For decades, preventive brain radiation has been a standard tool in the small-cell lung cancer (SCLC) playbook — but a major new trial is challenging that approach. The MAVERICK phase 3 trial, presented at the World Conference on Lung Cancer 2026 in Seoul, found that brain MRI surveillance alone reduced the risk of cognitive failure or death by 40% compared to MRI plus prophylactic cranial irradiation (PCI) in over 300 SCLC patients.
The trial enrolled 304 patients (68% with limited-stage disease) across 139 institutions globally. While PCI did reduce the rate of brain metastases at 12 months, it came with a steep toxicity cost — and no meaningful survival benefit was observed in the preliminary analysis.
By the Numbers:
Why it matters: These findings push back against a long-standing standard of care, suggesting that routine brain MRI monitoring may protect cognition and quality of life better than preventive radiation — without sacrificing survival. Final OS data and results from the ongoing PRIMALung trial are still needed, particularly for limited-stage disease, but MRI surveillance is increasingly looking like the preferred path forward.
